Tagged Articles

Eli Lilly 34 articles

New diabetes drugs have to provide more proof they are safe

These days, drugs to treat diabetes have one of the highest safety standards to clear before they are granted approval by the Food and Drug Administration (FDA). Placebo-controlled studies are no longer enough to sway agency decision makers. Drug companies must prove their new diabetes treatments won’t cause more problems than the condition they are treating. Which is why excitement over promising data from phase II studies on LY2605541, a joint effort by Eli Lilly and Boehringer Ingelheim, is contained. The drug showed better or equal glycemic control for patients with type 1 or type 2 diabetes than other similar ... Read More

Lawsuit accuses Takeda of hiding bladder cancer Actos risks

A Kentucky man is suing Actos manufacturer Takeda Pharmaceuticals, claiming the popular diabetes drug caused him to develop bladder cancer. The man and his wife filed the lawsuit in Los Angeles Superior Court, naming Japan-based Takeda and its subsidiary companies as defendants, as well as U.S.-based Eli Lilly, which partnered with Takeda to market Actos in the United States and Canada. In addition to bladder cancer and resulting illnesses, the plaintiffs assert Actos caused other bodily injuries, diminished enjoyment of life, economic losses, and other damages. According to the lawsuit, the link between Actos and bladder cancer was no secret ... Read More

Actos maker Takeda buys U.S. gout drug manufacturer

Japanese pharmaceutical giant Takeda, which produces the controversial diabetes drug Actos, is expanding its U.S. reach with an $800-million takeover of URL Pharma Inc. The move comes as Takeda’s U.S. profits are set to contract after Actos loses its patent protection later this year. Among other drugs, Philadephia-based URL manufactures Colcrys, an oral drug that is used to treat gout flare-ups. Colcrys is URL’s top moneymaker, earning the company $430 million in revenue last year. Takeda is Japan’s largest pharmaceutical company, but most of its sales revenues come from the United States, according to the Associated Press. Its top-earning drug ... Read More

BA lawyer appointed to help manage Actos bladder cancer litigation

Nineteen plaintiffs attorneys, including Beasley Allen attorney Andy Birchfield, have been appointed to manage litigation involving claims that Takeda Pharmaceuticals Co.’s type 2 diabetes drug Actos causes bladder cancer. Takeda, Asia’s largest drug maker, may face as many as 10,000 bladder cancer claims with Actos after a study showed that use the drug put users at risk for the disease. Federal lawsuits against Takeda were previously consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana. The first hearing is set for March 22. The lawsuits allege patients who used Actos are at an increased risk for developing bladder cancer, ... Read More

Lawsuits mount against Actos diabetes drug maker

If you have taken the type 2 diabetes drug Actos and were diagnosed with bladder cancer, you may have a case against the manufacturer. More and more lawsuits are being filed against Takeda Pharmaceuticals by people who claim the company knew the drug could cause cancer but intentionally hid it from the public. Among the latest lawsuits to be filed are those by three couples in Illinois. The lawsuits say the men took Actos as part of their doctors’ plans to treat their type 2 diabetes. It wasn’t until years later the men allege they learned that the medication they ... Read More

Actos bladder cancer lawsuits consolidated in Louisiana

Lawsuits against drug company Takeda claiming its type 2 diabetes drug Actos causes bladder cancer have been consolidated before one judge in federal court in Louisiana. The Federal Judicial Panel on Multidistrict Litigation sent the lawsuits to the Western District of Louisiana in Layfayette. U.S. District Judge Rebecca Doherty will oversee pretrial proceedings including evidence gathering in the lawsuit. The lawsuits claim that patients were put at increased risk for developing bladder cancer by using Actos to treat their type 2 diabetes. The plaintiffs also allege that Takeda and co-defendant Eli Lily & Co. withheld evidence that showed that Actos ... Read More

Bladder cancer victim files lawsuit against Actos maker

An Illinois man is suing the makers of the type 2 diabetes drug Actos, claiming the drug caused him to develop bladder cancer. His lawsuit alleges that the drug company was fully aware that the medication had been linked to bladder cancer but hid the risks from the public. The lawsuit was filed earlier this month in Madison County Circuit Court against Actos makers Takeda Pharmaceuticals America Inc., Takeda Pharmaceuticals North America Inc., Takeda Pharmaceutical Company Limited, and Eli Lilly and Company. The plaintiff was prescribed Actos in 2007 for the long-term control of his high blood sugar. He says he ... Read More

Class action lawsuit filed in Canada against Actos maker

A class action lawsuit has been filed in Canada against Takeda Pharmaceutical Company, the manufacturer and distributor of Actos (pioglitazone hydrochloride), and Eli Lilly, the drug company’s former distributor, alleging the drug companies failed to disclose that taking the type 2 diabetes drug for longer than a year increased the chances of developing bladder cancer. The lawsuit was filed with the Ontario Superior Court of Justice. The lead plaintiff in the case is a Toronto woman who was prescribed Actos in 2002. She died two years after being diagnosed with bladder cancer. Her daughter alleges that her mother would never ... Read More

Bladder cancer lawsuit filed against diabetes drug Actos

Robert Bettorf alleges the type 2 diabetes drug Actos caused him to develop bladder cancer, a side effect of the drug he says drug makers Takeda and Eli Lilly were aware of but about which they failed to warn consumers. He is suing the drug companies for strict liability, negligent failure to warn, negligent design defect, negligence, breach of express warranty, breach of implied warranty, negligent misrepresentation, violation of Illinois Consumer Protection Laws, and loss of consortium. Bettorf’s lawsuit claims that the drug companies were aware of the risks associated with Actos as early as 2005, but kept the information ... Read More